Mass cytometry Analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma

Cancer Immunology Research

Volumn 3, Issue 6, 2015, Pages 650-660

  Hansmann, Leo ^a   Blum, Lisa ^b   Ju, Chia Hsin ^b   Liedtke, Michaela ^c   Robinson, William H ^b   Davis, Mark M ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CCR7; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE SYK; IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ARTICLE; ASYMPTOMATIC MYELOMA; B LYMPHOCYTE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL HOMING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN GENE; INTRACELLULAR SIGNALING; MALE; MASS CYTOMETRY; MEMORY CELL; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA; NATURAL KILLER CELL; NEXT GENERATION SEQUENCING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMA CELL LEUKEMIA; PRECANCER; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; TIME OF FLIGHT MASS SPECTROMETRY; VERY ELDERLY; BONE MARROW; CANCER STAGING; CELL PROLIFERATION; CHROMOSOME ABERRATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL; MUTATION; PATHOLOGY; PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; B-LYMPHOCYTES; BONE MARROW; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; NEOPLASM STAGING; PHENOTYPE; PHOSPHORYLATION; RECEPTORS, ANTIGEN, B-CELL; TOLL-LIKE RECEPTOR 9;

EID: 84961911828     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0236-T     Document Type: Article

References (38)

1. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95.
2. Olechnowicz SW, Edwards CM. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res 2014;74:1625-31.
3. Restifo NP. A "big data" view of the tumor "immunome". Immunity 2013;39:631-2.
4. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011;332:687-96.
5. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by timeofflight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 2012;36:142-52.
6. Newell EW, Sigal N, Nair N, Kidd BA, Greenberg HB, Davis MM. Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat Biotechnol 2013;31:623-9.
7. Lu DR, Tan YC, Kongpachith S, Cai X, Stein EA, Lindstrom TM, et al. Identifying functional anti-Staphylococcus aureus antibodies by sequencing antibody repertoires of patient plasmablasts. Clin Immunol 2014;152:77-89.
8. Tan YC, Blum LK, Kongpachith S, Ju CH, Cai X, Lindstrom TM, et al. Highthroughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination. Clin Immunol 2014;151:55-65.
9. Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011;48:4-12.
10. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-7.
11. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113:5418-22.
12. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439-44.
13. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC. Multiplemyeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007;101:950-68.
14. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000.
15. de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, et al. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res 2013;19:5591-601.
16. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18.
17. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30.
18. Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
19. Bruggner RV, Bodenmiller B, Dill DL, Tibshirani RJ, Nolan GP. Automated identification of stratifying signatures in cellular subpopulations. ProcNatl Acad Sci U S A 2014;111:E2770-7.
20. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005;105:4390-8.
21. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig) M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-89.
22. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumorinfiltrating nonmalignant B cells. Blood 2006;108:3135-42.
23. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002;3:1129-34.
24. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, et al. Clonal cytotoxic T cells are expanded inmyeloma and reside in the CD8 (+) CD57 (+) CD28 (-) compartment. Blood 2001;98:2817-27.
25. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 2013;3:e148.
26. Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, et al. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma 2014;55:1090-8.
27. Feng P, Yan R, Dai X, Xie X, Wen H, Yang S. The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma. Inflammation 2014;38:705-9.
28. Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood 1997;90:340-5.
29. Seifert M, Kuppers R. Molecular footprints of a germinal center derivation of human IgM+ (IgD+) CD27+ B cells and the dynamics of memory B cell generation. J Exp Med 2009;206:2659-69.
30. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, Ito S, et al. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997;27:2073-9.
31. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010;95:1016-20.
32. Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006;203:1859-65.
33. Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010;24 Suppl 1:S5-11.
34. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-7.
35. Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 2014;28:2060-5.
36. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-6.
37. Thiago LS, Perez-Andres M, Balanzategui A, Sarasquete ME, Paiva B, Jara-Acevedo M, et al. Circulating clonotypic B-cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014;99:155-62.
38. Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006;177:1581-9.